search
Back to results

The Vesalio NeVa Stent Retriever Registry Study for Treatment of Large Vessel Occlusion Strokes

Primary Purpose

Acute Ischemic Stroke

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
NeVa Stent Retriever
Sponsored by
Vesalio
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Ischemic Stroke

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Only subjects already treated with the NeVa devices can be considered for enrollment.

  1. Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke, and subject belongs to one of the following subgroups:

    1.1. Subject has failed IV t-PA therapy

    1.2. Subject is contraindicated for IV t-PA administration

  2. Age ≥18
  3. NIHSS score ≥ 6
  4. Pre-stroke mRS score of ≤ 1
  5. Intracranial arterial occlusion of the distal intracranial carotid artery or middle cerebral artery (M1/M2), anterior cerebral artery (ACA), posterior cerebral artery (PCA), basilar artery, or vertebral artery demonstrated with DSA.
  6. Thrombectomy procedure can be initiated within 24 hours from symptom onset (defined as time last known well [TLKW])
  7. Imaging Inclusion Criteria:

    7.1. Non-Contrast CT Selection (if CT Perfusion or MRI not utilized): ASPECTS 6-10 if treatment started 0-6 hours from TLKW ASPECTS 8-10 if treatment started 6-24 hours from TLKW

    7.2. CT Perfusion core ≤50 cc

    7.3. MRI DWI core ≤50 cc

  8. Subject or legal representative is able and willing to give informed consent within 48 hours after the intervention.

Exclusion Criteria:

  1. Pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept).
  2. Cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing myocardial infarction, concern for pre- treatment pulmonary aspiration.
  3. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories
  4. Cerebral vasculitis
  5. History of severe allergy to contrast medium.
  6. Known allergy to NeVa materials (nitinol, stainless steel)
  7. Suspicion of aortic dissection, septic embolus, or bacterial endocarditis
  8. Systemic infection
  9. Significant mass effect with midline shift
  10. Evidence of intracranial tumor (except small meningioma)
  11. Inability to deploy NeVA device for at least one pass for any other reason
  12. Life expectancy less than 6 months
  13. Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.

Sites / Locations

  • Vall d'HebronRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Intervention

Arm Description

NeVa Stent Retriever

Outcomes

Primary Outcome Measures

Recanalization rate of occluded target vessel
Recanalization rate of occluded target vessel (defined by an eTICI score ≥ 2b) following three or less passes using the NeVa device(s).

Secondary Outcome Measures

Full Information

First Posted
April 18, 2019
Last Updated
January 12, 2023
Sponsor
Vesalio
search

1. Study Identification

Unique Protocol Identification Number
NCT03926988
Brief Title
The Vesalio NeVa Stent Retriever Registry Study for Treatment of Large Vessel Occlusion Strokes
Official Title
A Prospective, Open-Label, Multi-Center, Registry Designed to Assess the Safety, Performance and Efficacy of the NeVa Stent Retriever in the Treatment of Large Vessel Occlusion Strokes
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 1, 2019 (Actual)
Primary Completion Date
August 2024 (Anticipated)
Study Completion Date
August 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vesalio

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A prospective, open label, 90-day study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.
Detailed Description
This is a prospective, open label, multi-center registry designed to assess the safety, performance and efficacy of the NeVa stent retriever in the treatment of large vessel occlusion strokes. Up to 400 subjects at up 20 sites will participate in the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Ischemic Stroke

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Other
Arm Description
NeVa Stent Retriever
Intervention Type
Device
Intervention Name(s)
NeVa Stent Retriever
Intervention Description
mechanical neurothrombectomy
Primary Outcome Measure Information:
Title
Recanalization rate of occluded target vessel
Description
Recanalization rate of occluded target vessel (defined by an eTICI score ≥ 2b) following three or less passes using the NeVa device(s).
Time Frame
post-procedure day 0

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Only subjects already treated with the NeVa devices can be considered for enrollment. Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke, and subject belongs to one of the following subgroups: 1.1. Subject has failed IV t-PA therapy 1.2. Subject is contraindicated for IV t-PA administration Age ≥18 NIHSS score ≥ 6 Pre-stroke mRS score of ≤ 1 Intracranial arterial occlusion of the distal intracranial carotid artery or middle cerebral artery (M1/M2), anterior cerebral artery (ACA), posterior cerebral artery (PCA), basilar artery, or vertebral artery demonstrated with DSA. Thrombectomy procedure can be initiated within 24 hours from symptom onset (defined as time last known well [TLKW]) Imaging Inclusion Criteria: 7.1. Non-Contrast CT Selection (if CT Perfusion or MRI not utilized): ASPECTS 6-10 if treatment started 0-6 hours from TLKW ASPECTS 8-10 if treatment started 6-24 hours from TLKW 7.2. CT Perfusion core ≤50 cc 7.3. MRI DWI core ≤50 cc Subject or legal representative is able and willing to give informed consent within 48 hours after the intervention. Exclusion Criteria: Pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept). Cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing myocardial infarction, concern for pre- treatment pulmonary aspiration. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories Cerebral vasculitis History of severe allergy to contrast medium. Known allergy to NeVa materials (nitinol, stainless steel) Suspicion of aortic dissection, septic embolus, or bacterial endocarditis Systemic infection Significant mass effect with midline shift Evidence of intracranial tumor (except small meningioma) Inability to deploy NeVA device for at least one pass for any other reason Life expectancy less than 6 months Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Antoine Cuijpers
Phone
+31 6 51 55 99 37
Email
acuijpers@vesalio.com
Facility Information:
Facility Name
Vall d'Hebron
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marc Ribo, MD
Phone
932746000
Ext
6326
Email
marccriboj@hotmail.com

12. IPD Sharing Statement

Learn more about this trial

The Vesalio NeVa Stent Retriever Registry Study for Treatment of Large Vessel Occlusion Strokes

We'll reach out to this number within 24 hrs